Benitec Biopharma Inc. Common Stock
$11.02
-$0.34 (-2.99%)
$10.86Day Range$11.62
Key Statistics
Market Cap
$396.27M
Shares Outstanding
34.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 11, 2012
Round Lot
100
Locale
US
Trading Data
Day Open
$11.37
Day High
$11.62
Day Low
$10.86
Volume
423.0K
VWAP
$11.05
Prev Close
$11.36
Transactions
--
Acc. Volume
--
About Benitec Biopharma Inc. Common Stock
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.
PHARMACEUTICAL PREPARATIONSSIC 283424 employees3940 TRUST WAY, HAYWARD, CA, 94545(510) 780-0819IPO Jul 11, 2012US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001808898
- Composite FIGI
- BBG00R712L56
- Share Class FIGI
- BBG00R712L65
- Ticker Root
- BNTC
- SIC Code
- 2834
About Benitec Biopharma Inc. Common Stock (BNTC) Stock
Benitec Biopharma Inc. Common Stock (BNTC) closed the 2026-09-18 session at $11.02, down 2.99% versus the previous close (-0.34). The stock opened at $11.37 and traded between $10.86 and $11.62 during that session. Session trading volume was 423K shares. The volume-weighted average price (VWAP) is $11.05.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.
Benitec Biopharma Inc. Common Stock has a market capitalization of $396.3 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. BNTC is listed on the XNAS exchange. The company employs approximately 24 people. Benitec Biopharma Inc. Common Stock is headquartered in HAYWARD, CA. The recorded listing date is 2012-07-11.
On this page you can find market BNTC stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.